Study With a Topical Gel to Treat Common Warts in Adults
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00117871|
Recruitment Status : Completed
First Posted : July 11, 2005
Last Update Posted : February 19, 2007
The primary purpose of this study is to evaluate the effectiveness in adults of 2 different strengths of resiquimod gel applied to common wart(s) five times a week for up to 12 weeks.
A second purpose is to evaluate the safety of the drug.
|Condition or disease||Intervention/treatment||Phase|
|Warts||Drug: Resiquimod||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||48 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||A Two-Stage, Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Adults|
|Study Start Date :||October 2004|
- Clearance of treated wart(s)
- Partial clearance of treated wart(s)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00117871
|United States, Minnesota|
|Minnesota Clinical Study Center|
|Fridley, Minnesota, United States, 55432|